We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · March 02, 2017

PFS of Early Interim PET–Positive Patients With Advanced-Stage Hodgkin's Lymphoma Treated With BEACOPPescalated Alone or in Combination With Rituximab

The Lancet Oncology

 

Additional Info

The Lancet Oncology
Progression-Free Survival of Early Interim PET-Positive Patients With Advanced Stage Hodgkin's Lymphoma Treated With BEACOPPescalated Alone or in Combination With Rituximab (HD18): An Open-Label, International, Randomised Phase 3 Study by the German Hodgkin Study Group
Lancet Oncol 2017 Feb 21;[EPub Ahead of Print], P Borchmann, H Haverkamp, A Lohri, U Mey, S Kreissl, R Greil, J Markova, M Feuring-Buske, J Meissner, U Dührsen, H Ostermann, U Keller, G Maschmeyer, G Kuhnert, M Dietlein, C Kobe, H Eich, C Baues, H Stein, M Fuchs, V Diehl, A Engert

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading